4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $29.56.

Several analysts recently weighed in on FDMT shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday, May 24th. The Goldman Sachs Group cut their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Bank of America cut their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Finally, Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. BVF Inc. IL raised its position in shares of 4D Molecular Therapeutics by 70.8% during the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after acquiring an additional 1,890,647 shares during the last quarter. Vanguard Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after acquiring an additional 92,791 shares during the last quarter. Millennium Management LLC raised its position in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock worth $5,278,000 after acquiring an additional 213,264 shares during the last quarter. Federated Hermes Inc. raised its position in shares of 4D Molecular Therapeutics by 33,131.8% during the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after acquiring an additional 1,246,419 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of 4D Molecular Therapeutics by 159.5% during the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after acquiring an additional 504,086 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT traded up $0.13 during trading hours on Friday, hitting $3.75. The company's stock had a trading volume of 323,652 shares, compared to its average volume of 831,582. The stock has a fifty day simple moving average of $3.23 and a 200-day simple moving average of $4.76. The company has a market capitalization of $173.72 million, a P/E ratio of -1.32 and a beta of 2.87. 4D Molecular Therapeutics has a twelve month low of $2.24 and a twelve month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.